Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 19, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
On May 18, 2005, the GlaxoSmithKline Employee Trust ("the GSK Trust") transferred 13,609 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on May 19, 2005.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this filing.
Investor Verification Checklist
- Verify the total number of shares transferred from the GSK Trust (13,609 shares).
- Confirm the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Identify the directors with beneficial interests in the trust (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop).
- Note that this filing contains no financial performance metrics for the period.